Spandidos Publications Logo
  • About
    • About Spandidos
    • Aims and Scopes
    • Abstracting and Indexing
    • Editorial Policies
    • Reprints and Permissions
    • Job Opportunities
    • Terms and Conditions
    • Contact
  • Journals
    • All Journals
    • Oncology Letters
      • Oncology Letters
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Oncology
      • International Journal of Oncology
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Molecular and Clinical Oncology
      • Molecular and Clinical Oncology
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Experimental and Therapeutic Medicine
      • Experimental and Therapeutic Medicine
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Molecular Medicine
      • International Journal of Molecular Medicine
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Biomedical Reports
      • Biomedical Reports
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Oncology Reports
      • Oncology Reports
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Molecular Medicine Reports
      • Molecular Medicine Reports
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • World Academy of Sciences Journal
      • World Academy of Sciences Journal
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Functional Nutrition
      • International Journal of Functional Nutrition
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Epigenetics
      • International Journal of Epigenetics
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Medicine International
      • Medicine International
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
  • Articles
  • Information
    • Information for Authors
    • Information for Reviewers
    • Information for Librarians
    • Information for Advertisers
    • Conferences
  • Language Editing
Spandidos Publications Logo
  • About
    • About Spandidos
    • Aims and Scopes
    • Abstracting and Indexing
    • Editorial Policies
    • Reprints and Permissions
    • Job Opportunities
    • Terms and Conditions
    • Contact
  • Journals
    • All Journals
    • Biomedical Reports
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Experimental and Therapeutic Medicine
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Epigenetics
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Functional Nutrition
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Molecular Medicine
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Oncology
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Medicine International
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Molecular and Clinical Oncology
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Molecular Medicine Reports
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Oncology Letters
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Oncology Reports
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • World Academy of Sciences Journal
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
  • Articles
  • Information
    • For Authors
    • For Reviewers
    • For Librarians
    • For Advertisers
    • Conferences
  • Language Editing
Login Register Submit
  • This site uses cookies
  • You can change your cookie settings at any time by following the instructions in our Cookie Policy. To find out more, you may read our Privacy Policy.

    I agree
Search articles by DOI, keyword, author or affiliation
Search
Advanced Search
presentation
Oncology Letters
Join Editorial Board Propose a Special Issue
Print ISSN: 1792-1074 Online ISSN: 1792-1082
Journal Cover
January-2027 Volume 33 Issue 1

Full Size Image

Sign up for eToc alerts
Recommend to Library

Journals

International Journal of Molecular Medicine

International Journal of Molecular Medicine

International Journal of Molecular Medicine is an international journal devoted to molecular mechanisms of human disease.

International Journal of Oncology

International Journal of Oncology

International Journal of Oncology is an international journal devoted to oncology research and cancer treatment.

Molecular Medicine Reports

Molecular Medicine Reports

Covers molecular medicine topics such as pharmacology, pathology, genetics, neuroscience, infectious diseases, molecular cardiology, and molecular surgery.

Oncology Reports

Oncology Reports

Oncology Reports is an international journal devoted to fundamental and applied research in Oncology.

Experimental and Therapeutic Medicine

Experimental and Therapeutic Medicine

Experimental and Therapeutic Medicine is an international journal devoted to laboratory and clinical medicine.

Oncology Letters

Oncology Letters

Oncology Letters is an international journal devoted to Experimental and Clinical Oncology.

Biomedical Reports

Biomedical Reports

Explores a wide range of biological and medical fields, including pharmacology, genetics, microbiology, neuroscience, and molecular cardiology.

Molecular and Clinical Oncology

Molecular and Clinical Oncology

International journal addressing all aspects of oncology research, from tumorigenesis and oncogenes to chemotherapy and metastasis.

World Academy of Sciences Journal

World Academy of Sciences Journal

Multidisciplinary open-access journal spanning biochemistry, genetics, neuroscience, environmental health, and synthetic biology.

International Journal of Functional Nutrition

International Journal of Functional Nutrition

Open-access journal combining biochemistry, pharmacology, immunology, and genetics to advance health through functional nutrition.

International Journal of Epigenetics

International Journal of Epigenetics

Publishes open-access research on using epigenetics to advance understanding and treatment of human disease.

Medicine International

Medicine International

An International Open Access Journal Devoted to General Medicine.

Journal Cover
January-2027 Volume 33 Issue 1

Full Size Image

Sign up for eToc alerts
Recommend to Library

  • Article
  • Citations
    • Cite This Article
    • Download Citation
    • Create Citation Alert
    • Remove Citation Alert
    • Cited By
  • Similar Articles
    • Related Articles (in Spandidos Publications)
    • Similar Articles (Google Scholar)
    • Similar Articles (PubMed)
  • Download PDF
  • Download XML
  • View XML

  • Supplementary Files
    • Supplementary_Data.pdf
Review Open Access

Residual gastric cancer risk after Helicobacter pylori eradication: Mucosal immune trajectories (Review)

  • Authors:
    • Jian Chen
    • Bolin Tang
    • Li Zhou
  • View Affiliations / Copyright

    Affiliations: Department of Laboratory Medicine, People's Hospital of Yuxi City, Yuxi, Yunnan 653100, P.R. China, School of Public Health, Dali University, Dali, Yunnan 671000, P.R. China
    Copyright: © Chen et al. This is an open access article distributed under the terms of Creative Commons Attribution License.
  • Article Number: 5
    |
    Published online on: November 6, 2026
       https://doi.org/10.3892/ol.2026.15940
  • Expand metrics +
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )
Cited By (CrossRef): 0 citations Loading Articles...

This article is mentioned in:


Abstract

Helicobacter pylori is the leading modifiable cause of noncardia gastric cancer. Eradication lowers the incidence of primary and metachronous gastric neoplasia, yet a clinically meaningful risk remains once extensive atrophy, intestinal metaplasia or dysplasia is established. Current surveillance incorporates infection status and structural disease burden but does not directly assess biological recovery of the gastric mucosa. The present review examined whether mucosal immune trajectories after eradication are heterogeneous and whether localized immune measurements could explain variation in residual risk beyond morphology and epithelial‑field alterations. Single‑cell and spatial studies of human tissue have identified infection‑ and precursor‑associated changes in myeloid differentiation, antigen presentation, T‑cell states, metaplastic epithelium and stroma. Longitudinal evidence is less developed. Selected mucosal T‑cell measurements support reversibility of specific responses, whereas gene‑expression, histologic and microbiome trajectories provide molecular, structural or contextual evidence. Outcome‑linked CD8‑associated trajectories provide the closest currently available clinical‑outcome immune evidence, but remain non‑functional proxies derived from a post‑resection population. A 2026 human single‑cell study further identified persistent stromal and immunosuppressive niche features in post‑eradication chronic atrophic gastritis, but did not provide paired longitudinal immune‑function measurements or prospective neoplastic outcomes. Among the studies identified through the present search, none combined confirmation of eradication, paired measurements of immune function, concurrent assessment of the epithelial field and prospective dysplasia or cancer outcomes in individuals without previous gastric neoplasia. Therefore, the available evidence supports heterogeneous tissue recovery rather than a validated persistent immune state. Clinical translation would require reproducible functional immune activity, or a functionally validated proxy, together with independent outcome association, external validation and a clinically meaningful improvement in surveillance decisions beyond established histologic staging and lesion extent. Until such evidence is available, candidate immune markers should remain research tools and should not modify guideline‑based surveillance.
View Figures

Figure 1

Competing trajectories of gastric
tissue recovery and residual risk after eradication. The dominant
pathway emphasizes established eradication-associated risk
reduction followed by heterogeneous tissue recovery. Solid arrows
denote directly observed post-eradication changes or established
structural associations; dashed arrows denote candidate or
unresolved relationships that require longitudinal validation.
Dotted connectors indicate baseline pathological modifiers. Studies
(13,14,19–24)
address eradication-associated risk reduction and residual risk.
Overall and metachronous risk reduction is supported by certain
studies (14,19–23),
whereas earlier analyses questioned the benefit once intestinal
metaplasia or dysplasia was established (13,24).
Paired or longitudinal immune and molecular trajectories are
represented by certain studies (53,54,76),
as well as structural trajectories (15,16),
microbial trajectories (35,36)
and direct post-eradication stromal/immune-associated remodeling in
chronic atrophic gastritis (55).
H. pylori, Helicobacter pylori; OLGIM, Operative Link on
Gastric Intestinal Metaplasia Assessment; Me, methyl group.

Figure 2

Tissue context of
infection-associated remodeling and candidate persistence after
eradication. The visually dominant left-to-right pathway separates
evidence-supported observations from relationships that still
require longitudinal validation. (A) The infection/precursor-stage
layer summarizes epithelial metaplasia, myeloid and
antigen-presentation programs, altered T-cell states and gastric
tissue-resident memory T-cell biology (56,57,61–64,69–75,90,91).
Reference 64 demonstrates a resident-memory CD8+ T-cell cluster in
a single ex vivo human gastric intestinal metaplasia biopsy
and should not be interpreted as evidence of post-eradication
persistence. (B) The candidate layer addresses whether such tissue
states persist within the same individuals, remain functionally
abnormal and predict outcomes independently of structural and
epithelial-field burden. The localized immune-stromal interactions
depicted in panel B represent tumor-stage mechanistic analogies
rather than direct evidence of post-eradication stromal remodeling
in gastric precursor mucosa (80–82).
Solid connectors denote evidence-supported associations; dashed
connectors denote indirect, candidate or hypothesis-level links.
APC, antigen-presenting cell; H. pylori, Helicobacter
pylori; ECM, extracellular matrix.

Figure 3

Longitudinal study pathway for
evaluating post-eradication mucosal immune trajectories. The main
pathway visually prioritizes baseline assessment, confirmation of
eradication, anatomically standardized paired tissue, follow-up and
clinical outcomes. Solid connectors denote required measurements or
evidence-supported analytical steps; dashed connectors denote
hypothesized biological links that remain to be validated.
Biological support requires exposure linkage, localization,
persistence and functional evidence, or a proxy validated against
immune function. Clinical translation additionally requires
independent outcome association, external validation, calibration,
incremental value and a meaningful effect on surveillance decisions
(59,60,65,66). A
signal that fails at either stage should remain a research
observation rather than a clinical risk marker. H. pylori,
Helicobacter pylori.
View References

1 

Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I and Jemal A: Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 74:229–263. 2024.PubMed/NCBI

2 

Smyth EC, Nilsson M, Grabsch HI, van Grieken NCT and Lordick F: Gastric cancer. Lancet. 396:635–648. 2020. View Article : Google Scholar : PubMed/NCBI

3 

de Martel C, Georges D, Bray F, Ferlay J and Clifford GM: Global burden of cancer attributable to infections in 2018: A worldwide incidence analysis. Lancet Glob Health. 8:e180–e190. 2020. View Article : Google Scholar : PubMed/NCBI

4 

Plummer M, Franceschi S, Vignat J, Forman D and de Martel C: Global burden of gastric cancer attributable to Helicobacter pylori. Int J Cancer. 136:487–490. 2015. View Article : Google Scholar : PubMed/NCBI

5 

Wroblewski LE, Peek RM Jr and Wilson KT: Helicobacter pylori and gastric cancer: Factors that modulate disease risk. Clin Microbiol Rev. 23:713–739. 2010. View Article : Google Scholar : PubMed/NCBI

6 

Amieva M and Peek RM Jr: Pathobiology of Helicobacter pylori-induced gastric cancer. Gastroenterology. 150:64–78. 2016. View Article : Google Scholar : PubMed/NCBI

7 

Polk DB and Peek RM Jr: Helicobacter pylori: Gastric cancer and beyond. Nat Rev Cancer. 10:403–414. 2010. View Article : Google Scholar : PubMed/NCBI

8 

Wizenty J and Sigal M: Helicobacter pylori, microbiota and gastric cancer-principles of microorganism-driven carcinogenesis. Nat Rev Gastroenterol Hepatol. 22:296–313. 2025. View Article : Google Scholar : PubMed/NCBI

9 

Correa P: Human gastric carcinogenesis: A multistep and multifactorial process-first American cancer society award lecture on cancer epidemiology and prevention. Cancer Res. 52:6735–6740. 1992.PubMed/NCBI

10 

Liabeuf D, Oshima M, Stange DE and Sigal M: Stem cells, Helicobacter pylori, and mutational landscape: Utility of preclinical models to understand carcinogenesis and to direct management of gastric cancer. Gastroenterology. 162:1067–1087. 2022. View Article : Google Scholar : PubMed/NCBI

11 

Malfertheiner P, Megraud F, Rokkas T, Gisbert JP, Liou JM, Schulz C, Gasbarrini A, Hunt RH, Leja M, O'Morain C, et al: Management of Helicobacter pylori infection: The Maastricht VI/Florence consensus report. Gut. 71:1724–1762. 2022. View Article : Google Scholar : PubMed/NCBI

12 

Dinis-Ribeiro M, Libânio D, Uchima H, Spaander MCW, Bornschein J, Matysiak-Budnik T, Tziatzios G, Santos-Antunes J, Areia M, Chapelle N, et al: Management of epithelial precancerous conditions and early neoplasia of the stomach (MAPS III): European society of gastrointestinal endoscopy (ESGE), European Helicobacter and microbiota study group (EHMSG) and European society of pathology (ESP) guideline update 2025. Endoscopy. 57:504–554. 2025. View Article : Google Scholar : PubMed/NCBI

13 

Chen HN, Wang Z, Li X and Zhou ZG: Helicobacter pylori eradication cannot reduce the risk of gastric cancer in patients with intestinal metaplasia and dysplasia: Evidence from a meta-analysis. Gastric Cancer. 19:166–175. 2016. View Article : Google Scholar : PubMed/NCBI

14 

Fu Q, Yu H, Liu M, Chen L, Chen W, Wang Z and Li W: Effect of Helicobacter pylori eradication on gastric cancer risk in patients with intestinal metaplasia or dysplasia: A meta-analysis of randomized controlled trials. Front Microbiol. 16:15305492025. View Article : Google Scholar : PubMed/NCBI

15 

Hung KH, Wu JJ, Yang HB, Su LJ and Sheu BS: Host Wnt/beta-catenin pathway triggered by Helicobacter pylori correlates with regression of gastric intestinal metaplasia after H. pylori eradication. J Med Microbiol. 58:567–576. 2009. View Article : Google Scholar : PubMed/NCBI

16 

Kodama M, Okimoto T, Mizukami K, Hirashita Y, Wada Y, Fukuda M, Matsunari O, Okamoto K, Ogawa R, Fukuda K, et al: Gastric mucosal changes, and sex differences therein, after Helicobacter pylori eradication: A long-term prospective follow-up study. J Gastroenterol Hepatol. 36:2210–2216. 2021. View Article : Google Scholar : PubMed/NCBI

17 

Shah SC, Wang AY, Wallace MB and Hwang JH: AGA clinical practice update on screening and surveillance in individuals at increased risk for gastric cancer in the United States: Expert review. Gastroenterology. 168:405–416.e1. 2025. View Article : Google Scholar : PubMed/NCBI

18 

Park JY: Population-based Helicobacter pylori screen-and-treat strategies for gastric cancer prevention: Guidance on implementation. IARC Working Group Reports Lyon (FR): International Agency for Research on Cancer; 2025

19 

Lee YC, Chiang TH, Chou CK, Tu YK, Liao WC, Wu MS and Graham DY: Association between Helicobacter pylori eradication and gastric cancer incidence: A systematic review and meta-analysis. Gastroenterology. 150:1113–1124.e5. 2016. View Article : Google Scholar : PubMed/NCBI

20 

Ford AC, Yuan Y, Park JY, Forman D and Moayyedi P: Eradication therapy to prevent gastric cancer in Helicobacterpylori-positive individuals: Systematic review and meta-analysis of randomized controlled trials and observational studies. Gastroenterology. 169:261–276. 2025. View Article : Google Scholar : PubMed/NCBI

21 

Choi IJ, Kook MC, Kim YI, Cho SJ, Lee JY, Kim CG, Park B and Nam BH: Helicobacter pylori therapy for the prevention of metachronous gastric cancer. N Engl J Med. 378:1085–1095. 2018. View Article : Google Scholar : PubMed/NCBI

22 

Choi IJ, Kim CG, Lee JY, Kim YI, Kook MC, Park B and Joo J: Family history of gastric cancer and Helicobacter pylori treatment. N Engl J Med. 382:427–436. 2020. View Article : Google Scholar : PubMed/NCBI

23 

Fukase K, Kato M, Kikuchi S, Inoue K, Uemura N, Okamoto S, Terao S, Amagai K, Hayashi S and Asaka M; Japan Gast Study Group, : Effect of eradication of Helicobacter pylori on incidence of metachronous gastric carcinoma after endoscopic resection of early gastric cancer: An open-label, randomised controlled trial. Lancet. 372:392–397. 2008. View Article : Google Scholar : PubMed/NCBI

24 

Rokkas T, Rokka A and Portincasa P: A systematic review and meta-analysis of the role of Helicobacter pylori eradication in preventing gastric cancer. Ann Gastroenterol. 30:414–423. 2017.PubMed/NCBI

25 

Rugge M, Genta RM, Fassan M, Valentini E, Coati I, Guzzinati S, Savarino E, Zorzi M, Farinati F and Malfertheiner P: OLGA gastritis staging for the prediction of gastric cancer risk: A long-term follow-up study of 7436 patients. Am J Gastroenterol. 113:1621–1628. 2018. View Article : Google Scholar : PubMed/NCBI

26 

Capelle LG, de Vries AC, Haringsma J, Ter Borg F, de Vries RA, Bruno MJ, van Dekken H, Meijer J, van Grieken NCT and Kuipers EJ: The staging of gastritis with the OLGA system by using intestinal metaplasia as an accurate alternative for atrophic gastritis. Gastrointest Endosc. 71:1150–1158. 2010. View Article : Google Scholar : PubMed/NCBI

27 

Dixon MF, Genta RM, Yardley JH and Correa P: Classification and grading of gastritis: The updated sydney system. International workshop on the histopathology of gastritis, houston 1994. Am J Surg Pathol. 20:1161–1181. 1996. View Article : Google Scholar : PubMed/NCBI

28 

Pimentel-Nunes P, Libânio D, Marcos-Pinto R, Areia M, Leja M, Esposito G, Garrido M, Kikuste I, Megraud F, Matysiak-Budnik T, et al: Management of epithelial precancerous conditions and lesions in the stomach (MAPS II): European society of gastrointestinal endoscopy (ESGE), European Helicobacter and microbiota study group (EHMSG), European society of pathology (ESP), and sociedade portuguesa de endoscopia digestiva (SPED) guideline update 2019. Endoscopy. 51:365–388. 2019.PubMed/NCBI

29 

Sugano K, Tack J, Kuipers EJ, Graham DY, El-Omar EM, Miura S, Haruma K, Asaka M, Uemura N, Malfertheiner P, et al: Kyoto global consensus report on Helicobacter pylori gastritis. Gut. 64:1353–1367. 2015. View Article : Google Scholar : PubMed/NCBI

30 

den Hollander WJ, Holster IL, den Hoed CM, Capelle LG, Tang TJ, Anten MP, Prytz-Berset I, Witteman EM, ter Borg F, Hartog G, et al: Surveillance of premalignant gastric lesions: A multicentre prospective cohort study from low incidence regions. Gut. 68:585–593. 2019. View Article : Google Scholar : PubMed/NCBI

31 

Marcos P, Brito-Gonçalves G, Libânio D, Pita I, Castro R, Sá I, Dinis-Ribeiro M and Pimentel-Nunes P: Endoscopic grading of gastric intestinal metaplasia on risk assessment for early gastric neoplasia: Can we replace histology assessment also in the west? Gut. 69:1762–1768. 2020. View Article : Google Scholar : PubMed/NCBI

32 

El-Omar EM, Carrington M, Chow WH, McColl KE, Bream JH, Young HA, Herrera J, Lissowska J, Yuan CC, Rothman N, et al: Interleukin-1 polymorphisms associated with increased risk of gastric cancer. Nature. 404:398–402. 2000. View Article : Google Scholar : PubMed/NCBI

33 

González CA, Sala N and Capellá G: Genetic susceptibility and gastric cancer risk. Int J Cancer. 100:249–260. 2002. View Article : Google Scholar : PubMed/NCBI

34 

Tsugane S and Sasazuki S: Diet and the risk of gastric cancer: Review of epidemiological evidence. Gastric Cancer. 10:75–83. 2007. View Article : Google Scholar : PubMed/NCBI

35 

Sung JJY, Coker OO, Chu E, Szeto CH, Luk STY, Lau HCH and Yu J: Gastric microbes associated with gastric inflammation, atrophy and intestinal metaplasia 1 year after Helicobacter pylori eradication. Gut. 69:1572–1580. 2020. View Article : Google Scholar : PubMed/NCBI

36 

Song CH, Choi Y, Kim N, Ha S, Park JH, Lee HK, Shin CM and Ahn S: Longitudinal remodeling of gastric microbiota following Helicobacter pylori eradication reveals an eradication-associated microbial signature in gastric cancer. Front Cell Infect Microbiol. 16:18484372026. View Article : Google Scholar : PubMed/NCBI

37 

Ferreira RM, Pereira-Marques J, Pinto-Ribeiro I, Costa JL, Carneiro F, Machado JC and Figueiredo C: Gastric microbial community profiling reveals a dysbiotic cancer-associated microbiota. Gut. 67:226–236. 2018. View Article : Google Scholar : PubMed/NCBI

38 

Coker OO, Dai Z, Nie Y, Zhao G, Cao L, Nakatsu G, Wu WKK, Wong SH, Chen Z, Sung JJY and Yu J: Mucosal microbiome dysbiosis in gastric carcinogenesis. Gut. 67:1024–1032. 2018. View Article : Google Scholar : PubMed/NCBI

39 

Gantuya B, El-Serag HB, Matsumoto T, Ajami NJ, Oyuntsetseg K, Azzaya D, Uchida T and Yamaoka Y: Gastric microbiota in Helicobacter pylori-negative and -positive gastritis among high incidence of gastric cancer area. Cancers (Basel). 11:5042019. View Article : Google Scholar : PubMed/NCBI

40 

Salama NR, Hartung ML and Müller A: Life in the human stomach: Persistence strategies of the bacterial pathogen Helicobacter pylori. Nat Rev Microbiol. 11:385–399. 2013. View Article : Google Scholar : PubMed/NCBI

41 

Backert S, Tegtmeyer N and Fischer W: Composition, structure and function of the Helicobacter pylori cag pathogenicity island encoded type IV secretion system. Future Microbiol. 10:955–965. 2015. View Article : Google Scholar : PubMed/NCBI

42 

Hatakeyama M: Oncogenic mechanisms of the Helicobacter pylori CagA protein. Nat Rev Cancer. 4:688–694. 2004. View Article : Google Scholar : PubMed/NCBI

43 

Cover TL and Blaser MJ: Helicobacter pylori in health and disease. Gastroenterology. 136:1863–1873. 2009. View Article : Google Scholar : PubMed/NCBI

44 

Boquet P and Ricci V: Intoxication strategy of Helicobacter pylori VacA toxin. Trends Microbiol. 20:165–174. 2012. View Article : Google Scholar : PubMed/NCBI

45 

Fischer W: Assembly and molecular mode of action of the Helicobacter pylori Cag type IV secretion apparatus. FEBS J. 278:1203–1212. 2011. View Article : Google Scholar : PubMed/NCBI

46 

Murata-Kamiya N, Kurashima Y, Teishikata Y, Yamahashi Y, Saito Y, Higashi H, Aburatani H, Akiyama T, Peek RM Jr, Azuma T and Hatakeyama TM: Helicobacter pylori CagA interacts with E-cadherin and deregulates the beta-catenin signal that promotes intestinal transdifferentiation in gastric epithelial cells. Oncogene. 26:4617–4626. 2007. View Article : Google Scholar : PubMed/NCBI

47 

Bessède E, Dubus P, Mégraud F and Varon C: Helicobacter pylori infection and stem cells at the origin of gastric cancer. Oncogene. 34:2547–2555. 2015. View Article : Google Scholar : PubMed/NCBI

48 

Hayakawa Y, Fox JG and Wang TC: The origins of gastric cancer from gastric stem cells: Lessons from mouse models. Cell Mol Gastroenterol Hepatol. 3:331–338. 2017. View Article : Google Scholar : PubMed/NCBI

49 

Houghton J, Stoicov C, Nomura S, Rogers AB, Carlson J, Li H, Cai X, Fox JG, Goldenring JR and Wang TC: Gastric cancer originating from bone marrow-derived cells. Science. 306:1568–1571. 2004. View Article : Google Scholar : PubMed/NCBI

50 

Kusters JG, van Vliet AHM and Kuipers EJ: Pathogenesis of Helicobacter pylori infection. Clin Microbiol Rev. 19:449–490. 2006. View Article : Google Scholar : PubMed/NCBI

51 

Peek RM Jr and Blaser MJ: Helicobacter pylori and gastrointestinal tract adenocarcinomas. Nat Rev Cancer. 2:28–37. 2002. View Article : Google Scholar : PubMed/NCBI

52 

Uemura N, Okamoto S, Yamamoto S, Matsumura N, Yamaguchi S, Yamakido M, Taniyama K, Sasaki N and Schlemper RJ: Helicobacter pylori infection and the development of gastric cancer. N Engl J Med. 345:784–789. 2001. View Article : Google Scholar : PubMed/NCBI

53 

Ihan A, Tepez B, Gubina M, Malovrh T and Kopitar A: Diminished interferon-gamma production in gastric mucosa T lymphocytes after H. pylori eradication in duodenal ulcer patients. Hepatogastroenterology. 46:1740–1745. 1999.PubMed/NCBI

54 

Kim MJ, Je Y, Chun J, Youn YH, Park H, Nahm JH and Kim JH: Helicobacter pylori eradication is associated with a reduced risk of metachronous gastric neoplasia by restoring immune function in the gastric mucosa. Helicobacter. 30:e700302025. View Article : Google Scholar : PubMed/NCBI

55 

Fu Y, Tong J, Zhu M, Xu L, Huang F, Zhang Y, Wang X, Wang Z, Zhang J, Lv J, et al: Helicobacter pylori-induced inflammatory cancer transformation microenvironment drives gastric carcinogenesis. Cell Mol Gastroenterol Hepatol. 20:1017572026. View Article : Google Scholar : PubMed/NCBI

56 

Huang KK, Ma H, Chong RHH, Uchihara T, Lian BSX, Zhu F, Sheng T, Srivastava S, Tay ST, Sundar R, et al: Spatiotemporal genomic profiling of intestinal metaplasia reveals clonal dynamics of gastric cancer progression. Cancer Cell. 41:2019–2037.e8. 2023. View Article : Google Scholar : PubMed/NCBI

57 

Kim H, Kim J, Jeong IH, Park E, Yoo M, Yoon S, Lee D, Myung J, Choi E, Goldenring JR and Jang B: Hybrid identity and distinct methylation profiles of incomplete intestinal metaplasia in the stomach. Gut. 75:10–23. 2026. View Article : Google Scholar

58 

Curtius K, Wright NA and Graham TA: An evolutionary perspective on field cancerization. Nat Rev Cancer. 18:19–32. 2018. View Article : Google Scholar : PubMed/NCBI

59 

Collins GS, Reitsma JB, Altman DG and Moons KGM: Transparent reporting of a multivariable prediction model for individual prognosis or diagnosis (TRIPOD): The TRIPOD statement. Ann Intern Med. 162:55–63. 2015. View Article : Google Scholar : PubMed/NCBI

60 

McShane LM, Altman DG, Sauerbrei W, Taube SE, Gion M and Clark GM; Statistics Subcommittee of the NCI-EORTC Working Group on Cancer Diagnostics, : REporting recommendations for tumour MARKer prognostic studies (REMARK). Br J Cancer. 93:387–391. 2005. View Article : Google Scholar : PubMed/NCBI

61 

Hu W, Chen ZM, Wang Y, Yang C, Wu ZY, You LJ, Zhai ZY, Huang ZY, Zhou P, Huang SL, et al: Single-cell RNA sequencing dissects the immunosuppressive signatures in Helicobacter pylori-infected human gastric ecosystem. Nat Commun. 16:39032025. View Article : Google Scholar : PubMed/NCBI

62 

Huang RJ, Wichmann IA, Su A, Sathe A, Shum MV, Grimes SM, Meka R, Almeda A, Bai X, Shen J, et al: A spatial transcriptomic signature of 26 genes resolved at single-cell resolution characterizes high-risk gastric cancer precursors. NPJ Precis Oncol. 9:522025. View Article : Google Scholar : PubMed/NCBI

63 

Koch MRA, Gong R, Friedrich V, Engelsberger V, Kretschmer L, Wanisch A, Jarosch S, Ralser A, Lugen B, Quante M, et al: CagA-specific gastric CD8+ tissue-resident T cells control Helicobacter pylori during the early infection phase. Gastroenterology. 164:550–566. 2023. View Article : Google Scholar : PubMed/NCBI

64 

Law AMK, Chen J, Colino-Sanguino Y, Rodriguez de la Fuente L, Fang G, Grimes SM, Lu H, Huang RJ, Boyle ST, Venhuizen J, et al: ALTEN: A high-fidelity primary tissue-engineering platform to assess cellular responses ex vivo. Adv Sci (Weinh). 9:e21033322022. View Article : Google Scholar : PubMed/NCBI

65 

Wolff RF, Moons KGM, Riley RD, Whiting PF, Westwood M, Collins GS, Reitsma JB, Kleijnen J and Mallett S; PROBAST Group†, : PROBAST: A tool to assess the risk of bias and applicability of prediction model studies. Ann Intern Med. 170:51–58. 2019. View Article : Google Scholar : PubMed/NCBI

66 

Vickers AJ and Elkin EB: Decision curve analysis: A novel method for evaluating prediction models. Med Decis Making. 26:565–574. 2006. View Article : Google Scholar : PubMed/NCBI

67 

Netea MG, Domínguez-Andrés J, Barreiro LB, Chavakis T, Divangahi M, Fuchs E, Joosten LAB, van der Meer JWM, Mhlanga MM, Mulder WJM, et al: Defining trained immunity and its role in health and disease. Nat Rev Immunol. 20:375–388. 2020. View Article : Google Scholar : PubMed/NCBI

68 

Szabo PA, Miron M and Farber DL: Location, location, location: Tissue resident memory T cells in mice and humans. Sci Immunol. 4:eaas96732019. View Article : Google Scholar : PubMed/NCBI

69 

Sorini C, Tripathi KP, Wu S, Higdon SM, Wang J, Cheng L, Banerjee S, Reinhardt A, Kreslavsky T, Thorell A, et al: Metagenomic and single-cell RNA-Seq survey of the Helicobacter pylori-infected stomach in asymptomatic individuals. JCI Insight. 8:e1610422023. View Article : Google Scholar : PubMed/NCBI

70 

Li N, Chen S, Xu X, Wang H, Zheng P, Fei X, Ke H, Lei Y, Zhou Y, Yang X, et al: Single-cell transcriptomic profiling uncovers cellular complexity and microenvironment in gastric tumorigenesis associated with Helicobacter pylori. J Adv Res. 74:471–491. 2025. View Article : Google Scholar : PubMed/NCBI

71 

Nowicki-Osuch K, Zhuang L, Cheung TS, Black E, Masqué-Soler N, Devonshire G, Redmond A, Freeman A, di Pietro M, Pilonis N, et al: Single-cell RNA sequencing unifies developmental programs of esophageal and gastric intestinal metaplasia. Cancer Discov. 13:1346–1363. 2023. View Article : Google Scholar : PubMed/NCBI

72 

Kim J, Park C, Kim KH, Kim EH, Kim H, Woo JK, Seong JK, Nam KT, Lee YC and Cho SY: Single-cell analysis of gastric pre-cancerous and cancer lesions reveals cell lineage diversity and intratumoral heterogeneity. NPJ Precis Oncol. 6:92022. View Article : Google Scholar : PubMed/NCBI

73 

Chen X, Jiang X, Wang S, Xia J, Wang W, Fu X, Yukun P, Liu Z, Li Y, Zhang M and Ding Y: Integrated single-cell and spatial transcriptomics reveal the differentiation drivers of gastric epithelial lineage progression. Front Immunol. 17:17128302026. View Article : Google Scholar : PubMed/NCBI

74 

Ye Y, Gong X, Liu S, Hu N, Zhang H, Fei X, Huang A, Fan W, Chen Z, Wang H, et al: A single-cell multi-omics atlas defines the cellular and molecular landscape of gastric intestinal metaplasia. J Transl Med. 24:7242026. View Article : Google Scholar : PubMed/NCBI

75 

Yin H, Zhang H, Zheng S, Guo R, Wen J, Liu M, Li A, Zhao M, Yuan Y and Gong Y: Dissecting the differentiation origins of intestinal metaplasia and early intestinal-type gastric cancer in gastric antrum by single-cell RNA profiling. NPJ Precis Oncol. 10:1672026. View Article : Google Scholar : PubMed/NCBI

76 

Tsai CJ, Herrera-Goepfert R, Tibshirani RJ, Yang S, Mohar A, Guarner J and Parsonnet J: Changes of gene expression in gastric preneoplasia following Helicobacter pylori eradication therapy. Cancer Epidemiol Biomarkers Prev. 15:272–280. 2006. View Article : Google Scholar : PubMed/NCBI

77 

Kumar V, Ramnarayanan K, Sundar R, Padmanabhan N, Srivastava S, Koiwa M, Yasuda T, Koh V, Huang KK, Tay ST, et al: Single-cell atlas of lineage states, tumor microenvironment and subtype-specific expression programs in gastric cancer. Cancer Discov. 12:670–691. 2022. View Article : Google Scholar : PubMed/NCBI

78 

Zhang M, Hu S, Min M, Ni Y, Lu Z, Sun X, Wu J, Liu B, Ying X and Liu Y: Dissecting transcriptional heterogeneity in primary gastric adenocarcinoma by single cell RNA sequencing. Gut. 70:464–475. 2021. View Article : Google Scholar : PubMed/NCBI

79 

Murray PJ, Allen JE, Biswas SK, Fisher EA, Gilroy DW, Goerdt S, Gordon S, Hamilton JA, Ivashkiv LB, Lawrence T, et al: Macrophage activation and polarization: Nomenclature and experimental guidelines. Immunity. 41:14–20. 2014. View Article : Google Scholar : PubMed/NCBI

80 

Su Z, He Y, You L, Chen J, Zhang G and Liu Z: SPP1+ macrophages and FAP+ fibroblasts promote the progression of pMMR gastric cancer. Sci Rep. 14:262212024. View Article : Google Scholar : PubMed/NCBI

81 

Qiu L, Zhao X, Yao S, Fei Y, Gong Y, Zhou Z, Jiao S and Xu J: Multi-omics analyses reveal interactions between GREM1+ fibroblasts and SPP1+ macrophages in gastric cancer. NPJ Precis Oncol. 9:1642025. View Article : Google Scholar : PubMed/NCBI

82 

Ma G, Liu X, Jiang Q, Li S, Wu Q, Liang B, Sun F, Gu C, Liao W, Zhang Z, et al: Identification of a stromal immunosuppressive barrier orchestrated by SPP1+/C1QC+ macrophages and CD8+ exhausted T cells driving gastric cancer immunotherapy resistance. Front Immunol. 16:16185912025. View Article : Google Scholar : PubMed/NCBI

83 

Lundgren A, Suri-Payer E, Enarsson K, Svennerholm AM and Lundin BS: Helicobacter pylori-specific CD4+ CD25high regulatory T cells suppress memory T-cell responses to H. pylori in infected individuals. Infect Immun. 71:1755–1762. 2003. View Article : Google Scholar : PubMed/NCBI

84 

Amedei A, Cappon A, Codolo G, Cabrelle A, Polenghi A, Benagiano M, Tasca E, Azzurri A, D'Elios MM, DelPrete G and de Bernard M: The neutrophil-activating protein of Helicobacter pylori promotes Th1 immune responses. J Clin Invest. 116:1092–1101. 2006. View Article : Google Scholar : PubMed/NCBI

85 

Rad R, Brenner L, Bauer S, Schwendy S, Layland L, da Costa CP, Reindl W, Dossumbekova A, Friedrich M, Saur D, et al: CD25+/Foxp3+ T cells regulate gastric inflammation and Helicobacter pylori colonization in vivo. Gastroenterology. 131:525–537. 2006. View Article : Google Scholar : PubMed/NCBI

86 

Kao JY, Zhang M, Miller MJ, Mills JC, Wang B, Liu M, Eaton KA, Zou W, Berndt BE, Cole TS, et al: Helicobacter pylori immune escape is mediated by dendritic cell-induced Treg skewing and Th17 suppression in mice. Gastroenterology. 138:1046–1054. 2010. View Article : Google Scholar : PubMed/NCBI

87 

Oertli M, Noben M, Engler DB, Semper RP, Reuter S, Maxeiner J, Gerhard M, Taube C and Müller A: Helicobacter pylori γ-glutamyl transpeptidase and vacuolating cytotoxin promote gastric persistence and immune tolerance. Proc Natl Acad Sci USA. 110:3047–3052. 2013. View Article : Google Scholar : PubMed/NCBI

88 

Hitzler I, Sayi A, Kohler E, Engler DB, Koch KN, Hardt WD and Müller A: Caspase-1 has both proinflammatory and regulatory properties in Helicobacter infections, which are differentially mediated by its substrates IL-1β and IL-18. J Immunol. 188:3594–3602. 2012. View Article : Google Scholar : PubMed/NCBI

89 

Caruso R, Pallone F and Monteleone G: Emerging role of IL-23/IL-17 axis in H pylori-associated pathology. World J Gastroenterol. 13:5547–5551. 2007. View Article : Google Scholar : PubMed/NCBI

90 

Xia T, Zhang Z, Xie J, Yuan H, Ren Y, Xu Y, Ning J, Li B and Wu C: Gastric mucosal CD8+TRM cells are recruited through CXCR5-CXCL13 axis in Helicobacter pylori infected subjects. Cytokine. 190:1569042025. View Article : Google Scholar : PubMed/NCBI

91 

Gong R, Huang B, Ralser A, Friedrich V, Mibus C, Engelsberger V, Koch MRA, Skerhut M, Giese T, Andrä I, et al: CagA-dependent Hobit+ gastric tissue-resident memory T cells confer full protection from Helicobacter pylori reinfection. Gut. 74:1792–1803. 2025. View Article : Google Scholar : PubMed/NCBI

92 

Bockerstett KA, Lewis SA, Noto CN, Ford EL, Saenz JB, Jackson NM, Ahn TH, Mills JC and DiPaolo RJ: Single- cell transcriptional analyses identify lineage-specific epithelial responses to inflammation and metaplastic development in the gastric corpus. Gastroenterology. 159:2116–2129.e4. 2020. View Article : Google Scholar : PubMed/NCBI

93 

Petersen CP, Mills JC and Goldenring JR: Murine models of gastric corpus preneoplasia. Cell Mol Gastroenterol Hepatol. 3:11–26. 2016. View Article : Google Scholar : PubMed/NCBI

94 

Nam KT, Lee HJ, Sousa JF, Weis VG, O'Neal RL, Finke PE, Romero-Gallo J, Shi G, Mills JC, Peek RM Jr, et al: Mature chief cells are cryptic progenitors for metaplasia in the stomach. Gastroenterology. 139:2028–2037.e9. 2010. View Article : Google Scholar : PubMed/NCBI

95 

Goldenring JR and Nam KT: Oxyntic atrophy, metaplasia, and gastric cancer. Prog Mol Biol Transl Sci. 96:117–131. 2010. View Article : Google Scholar : PubMed/NCBI

96 

Mills JC and Goldenring JR: Metaplasia in the stomach arises from gastric chief cells. Cell Mol Gastroenterol Hepatol. 4:85–88. 2017. View Article : Google Scholar : PubMed/NCBI

97 

Coussens LM and Werb Z: Inflammation and cancer. Nature. 420:860–867. 2002. View Article : Google Scholar : PubMed/NCBI

98 

Mantovani A, Allavena P, Sica A and Balkwill F: Cancer-related inflammation. Nature. 454:436–444. 2008. View Article : Google Scholar : PubMed/NCBI

99 

Cancer Genome Atlas Research Network, . Comprehensive molecular characterization of gastric adenocarcinoma. Nature. 513:202–209. 2014. View Article : Google Scholar : PubMed/NCBI

100 

Cristescu R, Lee J, Nebozhyn M, Kim KM, Ting JC, Wong SS, Liu J, Yue YG, Wang J, Yu K, et al: Molecular analysis of gastric cancer identifies subtypes associated with distinct clinical outcomes. Nat Med. 21:449–456. 2015. View Article : Google Scholar : PubMed/NCBI

101 

Banks M, Graham D, Jansen M, Gotoda T, Coda S, di Pietro M, Uedo N, Bhandari P, Pritchard DM, Kuipers EJ, et al: British society of gastroenterology guidelines on the diagnosis and management of patients at risk of gastric adenocarcinoma. Gut. 68:1545–1575. 2019. View Article : Google Scholar : PubMed/NCBI

102 

Sung JK: Diagnosis and management of gastric dysplasia. Korean J Intern Med. 31:201–209. 2016. View Article : Google Scholar : PubMed/NCBI

103 

Song L and Yu QY: Stratified management of residual gastric cancer risk after Helicobacter pylori eradication. Front Microbiol. 17:17794902026. View Article : Google Scholar : PubMed/NCBI

104 

Ding T, Hu W, Qi X, Zhang Y and Wang H: Advances in Helicobacter pylori-mediated oncogenic signaling pathways in gastric cancer: From pathological evolution to clinical application prospects (Review). Oncol Lett. 32:4082026. View Article : Google Scholar : PubMed/NCBI

105 

Guan Z, Han L, Chen B, Ma Y, Ni Q, Wang Z, Yang J and Liu Z: Tumor microenvironment in gastric cancer immune tolerance and its therapeutic relevance in immunomodulation (Review). Oncol Lett. 31:1082026. View Article : Google Scholar : PubMed/NCBI

106 

Moncada R, Barkley D, Wagner F, Chiodin M, Devlin JC, Baron M, Hajdu CH, Simeone DM and Yanai I: Integrating microarray-based spatial transcriptomics and single-cell RNA-seq reveals tissue architecture in pancreatic ductal adenocarcinomas. Nat Biotechnol. 38:333–342. 2020. View Article : Google Scholar : PubMed/NCBI

Related Articles

  • Abstract
  • View
  • Download
  • Twitter
Copy and paste a formatted citation
Spandidos Publications style
Chen J, Tang B and Zhou L: Residual gastric cancer risk after <em>Helicobacter pylori</em> eradication: Mucosal immune trajectories (Review). Oncol Lett 33: 5, 2027.
APA
Chen, J., Tang, B., & Zhou, L. (2027). Residual gastric cancer risk after <em>Helicobacter pylori</em> eradication: Mucosal immune trajectories (Review). Oncology Letters, 33, 5. https://doi.org/10.3892/ol.2026.15940
MLA
Chen, J., Tang, B., Zhou, L."Residual gastric cancer risk after <em>Helicobacter pylori</em> eradication: Mucosal immune trajectories (Review)". Oncology Letters 33.1 (2027): 5.
Chicago
Chen, J., Tang, B., Zhou, L."Residual gastric cancer risk after <em>Helicobacter pylori</em> eradication: Mucosal immune trajectories (Review)". Oncology Letters 33, no. 1 (2027): 5. https://doi.org/10.3892/ol.2026.15940
Copy and paste a formatted citation
x
Spandidos Publications style
Chen J, Tang B and Zhou L: Residual gastric cancer risk after <em>Helicobacter pylori</em> eradication: Mucosal immune trajectories (Review). Oncol Lett 33: 5, 2027.
APA
Chen, J., Tang, B., & Zhou, L. (2027). Residual gastric cancer risk after <em>Helicobacter pylori</em> eradication: Mucosal immune trajectories (Review). Oncology Letters, 33, 5. https://doi.org/10.3892/ol.2026.15940
MLA
Chen, J., Tang, B., Zhou, L."Residual gastric cancer risk after <em>Helicobacter pylori</em> eradication: Mucosal immune trajectories (Review)". Oncology Letters 33.1 (2027): 5.
Chicago
Chen, J., Tang, B., Zhou, L."Residual gastric cancer risk after <em>Helicobacter pylori</em> eradication: Mucosal immune trajectories (Review)". Oncology Letters 33, no. 1 (2027): 5. https://doi.org/10.3892/ol.2026.15940
Follow us
  • Twitter
  • LinkedIn
  • Facebook
About
  • Spandidos Publications
  • Careers
  • Cookie Policy
  • Privacy Policy
How can we help?
  • Help
  • Live Chat
  • Contact
  • Email to our Support Team